Lili Kuo Selected Research

Zika Virus Infection

4/2022	In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus.
12/2020	Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.
10/2020	JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo.
1/2020	Corrigendum: Zika Virus Infection Results in Biochemical Changes Associated With RNA Editing, Inflammatory and Antiviral Responses in Aedes albopictus.
1/2020	Zika Virus Infection Results in Biochemical Changes Associated With RNA Editing, Inflammatory and Antiviral Responses in Aedes albopictus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lili Kuo Research Topics

Disease

7	Infections 01/2022 - 08/2010
5	Zika Virus Infection 04/2022 - 01/2020
1	Viremia 12/2020
1	Flavivirus Infections 12/2020
1	Dengue (Dengue Fever) 01/2020
1	Hepatitis 08/2003

Drug/Important Bio-Agent (IBA)

3	Antiviral Agents (Antivirals)IBA 12/2020 - 01/2020
2	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2022 - 04/2014
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2020
1	Erythrosine (Erythrosin)IBA 04/2022
1	Food Additives (Food Additive)IBA 04/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Methylene Blue (Methylthioninium Chloride)FDA Link 12/2020
1	Peptide Hydrolases (Proteases)FDA Link 12/2020
1	Niclosamide FDA Link 10/2020
1	UridineIBA 01/2020
1	Inosine FDA Link 01/2020
1	Nucleocapsid ProteinsIBA 06/2015
1	UbiquitinIBA 06/2015
1	Interferon Type IIBA 08/2010
1	Coronavirus M ProteinsIBA 08/2003

Therapy/Procedure

1	Therapeutics 12/2020